# A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020

> **NCT01744808** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Normal, Healthy Volunteers

## Interventions

- **DRUG:** EB-1020 IR
- **DRUG:** EB-1020 SR1
- **DRUG:** EB-1020 SR2
- **DRUG:** EB-1020 SR3
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01744808
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-01
- **Primary completion:** 2014-02-01
- **Final completion:** 2014-02-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744808, "A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01744808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*